Earnings ·
OmniAb reports Q3 revenue of $4.0M, raises full-year outlook to $35-$39M
OABIOmniAb, Inc.
OmniAb reported third-quarter 2026 revenue of $4.0 million, up from $2.2 million in the prior year, driven by service and xPloration sales. The company posted a net loss of $15.7 million, or $0.12 per share, compared to a $16.5 million loss previously. For the nine months ended September 30, revenue reached $31.8 million against $10.3 million in the prior-year period. OmniAb raised its full-year 2026 revenue guidance to $35 million–$39 million and updated its cash outlook to end the year with $53 million–$57 million. The company also announced a new collaboration with Eli Lilly for an ion channel program, eligible for up to $370 million in milestones. OmniAb operates as a provider of discovery research technology to enable the development of next-generation therapeutics.